Identification and validation of an inflammation-related lncRNAs signature for improving outcomes of patients in colorectal cancer

Abstract

Background: Colorectal cancer is the fourth most deadly cancer worldwide. Although current treatment regimens have prolonged the survival of patients, the prognosis is still unsatisfactory. Inflammation and lncRNAs are closely related to tumor occurrence and development in CRC. Therefore, it is necessary to establish a new prognostic signature based on inflammation-related lncRNAs to improve the prognosis of patients with CRC.Methods: LASSO-penalized Cox analysis was performed to construct a prognostic signature. Kaplan-Meier curves were used for survival analysis and ROC curves were used to measure the performance of the signature. Functional enrichment analysis was conducted to reveal the biological significance of the signature. The R package “maftool” and GISTIC2.0 algorithm were performed for analysis and visualization of genomic variations. The R package “pRRophetic”, CMap analysis and submap analysis were performed to predict response to chemotherapy and immunotherapy.Results: An effective and independent prognostic signature, IRLncSig, was constructed based on sixteen inflammation-related lncRNAs. The IRLncSig was proved to be an independent prognostic indicator in CRC and was superior to clinical variables and the other four published signatures. The nomograms were constructed based on inflammation-related lncRNAs and detected by calibration curves. All samples were classified into two groups according to the median value, and we found frequent mutations of the TP53 gene in the high-risk group. We also found some significantly amplificated regions in the high-risk group, 8q24.3, 20q12, 8q22.3, and 20q13.2, which may regulate the inflammatory activity of cancer cells in CRC. Finally, we identified chemotherapeutic agents for high-risk patients and found that these patients were more likely to respond to immunotherapy, especially anti-CTLA4 therapy.Conclusion: In short, we constructed a new signature based on sixteen inflammation-related lncRNAs to improve the outcomes of patients in CRC. Our findings have proved that the IRLncSig can be used as an effective and independent marker for predicting the survival of patients with CRC.

LncRNA KIFAP3-5:1 inhibits epithelial-mesenchymal transition of renal tubular cell through PRRX1 in diabetic nephropathy

“…In the pathological development of DN, a significant number of lncRNAs with significant clinical relevance have been discovered. These lncRNAs, including Malat1, ANRIL, and PANDAR, can serve as reliable markers for prognostic prediction and early diagnosis of DN (Zhao et al 2020;Zhou et al 2020;Zhu et al 2022). In this study, the expression of KIFAP3-5:1 in plasma was significantly down-regulated in stage G3 of DN patients than those in healthy controls.…”

“…Long non-coding RNAs (LncRNA) are RNA transcripts that exceed a length of 200 nucleotides. They play an important regulatory role in various physiological and pathological processes, including cell proliferation Zhang et al 2021;Wu et al 2023;Huang et al 2022). LncRNAs, through their interactions with other RNA molecules or proteins, play a crucial role in the regulation of gene expression at both transcriptional and post-transcriptional levels (Xu et al 2022;Han et al 2022).…”

Long Non-Coding RNAs in Colorectal Cancer: Navigating the Intersections of Immunity, Intercellular Communication, and Therapeutic Potential

“…Dysregulated lncRNAs are increasingly being recognized as significant contributors to the pathogenesis of CRC immune evasion, and the response to therapy. Moreover, lncRNAs appear to be intricately connected to the inflammatory processes driving CRC, marking them as potential predictive biomarkers for treatment response [ 8 ].…”